

## UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/764,163	01/16/2001	Robert F. Balint	PARE.002.02US	7613
20350	7590 02/04/2003			
TOWNSEND AND TOWNSEND AND CREW, LLP			EXAMI	NER .
TWO EMBA EIGHTH FLO	RCADERO CENTÉR OOR	EPPERSON	N, JON D	
SAN FRANC	CISCO, CA 94111-3834		ART UNIT	PAPER NUMBER
			1639	سبرا
			DATE MAILED: 02/04/2003	C

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED SES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER FILING DAT	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/764,1631/16/200	1 Balint, Robert F.	PARE.002.02US

EXAMINER				
Jon D. Epperson, Ph. D.				
оси в герр	1			
ART UNIT	PAPER NUMBER			
1639	15			
DATE MAILED:				

Please find below a communication from the EXAMINER in charge of this application

Notice To Comply: Sequence Rules (Bonafide)

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the following reason(s): Figures 2 and 12 contain sequences without SEQ ID Nos. Please re-check the entire sepcification. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Please direct all replies to the Unite States Patent and Traemark Office via one (1) of the following:

1. Electronically submitted through EFS-Bio

(<< http://www.uspto.gov/ebc/efs/downloads/documents.htm>>, EFS Submisssion User Manual - ePAVE)

2. Mailed to:

U.S. Patent and Trademark Office Box Sequence, P.O. Box 2327 Arlington, VA 22202

Any inquiry concerning this communication should be directed to Jon D. Epperson whose telephone number is (703) 308-2423. The Examiner can normally be reached on Monday through Friday from 9 am to 6 pm. If attempts to reach the Examiner by telephone are unsuccessful, the Examiners's supervisor, Andrew Wang, can be reached at (703) 306-3217. The fax number for this group is (703) 305-3014. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the group receptionist whose telephone number is (703) 308-0196.

JON D. EPPERSON, Ph.D. PATENT EXAMINER

BENNETT CELSA

Application No.: <u>09/764,163</u>

## NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

X	<ol> <li>This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.</li> </ol>			
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).			
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).			
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."			
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).			
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).			
X	7. Other: Specification does not comply: Figure 2 and Figure 12 do not have SEQ ID Nos.			
Applicant Must Provide:				
X	An initial or <b>substitute</b> computer readable form (CRF) copy of the "Sequence Listing".			
X	An initial or <b>substitute</b> paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.			
X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).			
For	questions regarding compliance to these requirements, please contact:			
For	Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212 entIn Software Program Support (SIRA)			
	Technical Assistance			
	10 1 0101000 1 0101111 0011110			

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE